Dr. Liu Wenyi | Health Sciences | Best Researcher Award
Cancer Hospital Chinese Academy of Medical Sciences | China
Dr. Liu Wenyi is a thoracic-surgery specialist whose research focuses on advanced treatments for thoracic malignancies especially esophageal and lung cancers emphasising organ-preservation strategies, neoadjuvant chemo-/chemo-immunotherapy, imaging- and machine-learning-based response assessment, and translational biomarkers for surgical decision-making. His work has contributed to the evolving paradigm of less-invasive surgery and more personalised multimodal care. For example, his recent narrative review “Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions” is a state-of-the-field synthesis published in Cancers highlighting novel surveillance-based approaches in esophageal squamous cell carcinoma. His Google Scholar/Scopus profile indicates approximately 10 publications and a current h-index of 5 (citations ~80) under his name. This volume reflects a mid-career emerging investigator whose trajectory is marked by high-impact topics (thoracic oncology, immunotherapy, AI-enabled imaging) and whose top publications already appear in high-visibility journals. Dr. Liu’s work is characterized by integrating minimally invasive surgical techniques, cutting-edge neoadjuvant systemic treatments and advanced predictive modelling to stratify patients for surgical risk and organ-sparing pathways thus contributing to both improved patient quality of life and optimized oncologic outcomes.His outstanding contributions to clinical innovation and scientific research excellence reflect strong merit for recognition under the Best Researcher Award .
Publication Profile
Orcid
Featured Publications
Liu, W., Guo, X., Zhao, H., Yu, X., Wang, C., Du, L., Wang, F., & Mu, J. (2020). Mediastinoscopy-assisted transhiatal esophagectomy versus thoraco-laparoscopic esophagectomy for esophageal cancer: A single-center initial experience. Journal of Thoracic Disease, 12(9), 4908-4914.
Liu, W., Tang, J., Li, X., Gong, L., Yang, D., Yin, H., Wang, W., & Zhang, B. (2025). Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer. Oncology Letters, 30(5), 501.
Liu, W., Sui, Z., Wang, C., Deng, Y., Cai, S., Jia, R., Yu, Z., Kang, M., & Zhang, B. (2025). Nomogram for predicting pathological complete response to neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer. Frontiers in Cell and Developmental Biology, 13, 1679782.
Hong, Z., Xie, S., Xu, H., Ke, S., Liu, W., Huang, S., Chen, S., Xie, J., Xu, J., & Kang, M. (2025). Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study. European Journal of Surgical Oncology, 51(2), 109500.
Liu, W., Zhang, B., Wang, C., Yu, X., Du, L., Yu, Z., & Kang, M. (2025). Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions. Cancers, 17(21), 3559.